nodes	percent_of_prediction	percent_of_DWPC	metapath
Minocycline—MMP9—urinary bladder cancer	0.531	1	CbGaD
Minocycline—SLC22A7—Fluorouracil—urinary bladder cancer	0.0704	0.37	CbGbCtD
Minocycline—SLC22A11—Methotrexate—urinary bladder cancer	0.0407	0.214	CbGbCtD
Minocycline—SLC22A7—Methotrexate—urinary bladder cancer	0.0388	0.204	CbGbCtD
Minocycline—SLC22A8—Methotrexate—urinary bladder cancer	0.0237	0.125	CbGbCtD
Minocycline—SLC22A6—Methotrexate—urinary bladder cancer	0.0165	0.0868	CbGbCtD
Minocycline—CASP1—prostate gland—urinary bladder cancer	0.00398	0.04	CbGeAlD
Minocycline—CYCS—prostate gland—urinary bladder cancer	0.00383	0.0385	CbGeAlD
Minocycline—CASP1—seminal vesicle—urinary bladder cancer	0.00336	0.0338	CbGeAlD
Minocycline—CASP3—prostate gland—urinary bladder cancer	0.00328	0.033	CbGeAlD
Minocycline—SLC22A8—urine—urinary bladder cancer	0.00325	0.0327	CbGeAlD
Minocycline—CASP1—epithelium—urinary bladder cancer	0.00292	0.0294	CbGeAlD
Minocycline—CYCS—epithelium—urinary bladder cancer	0.00281	0.0283	CbGeAlD
Minocycline—CASP3—seminal vesicle—urinary bladder cancer	0.00277	0.0279	CbGeAlD
Minocycline—CASP1—renal system—urinary bladder cancer	0.00271	0.0273	CbGeAlD
Minocycline—CYCS—smooth muscle tissue—urinary bladder cancer	0.00271	0.0273	CbGeAlD
Minocycline—CASP1—urethra—urinary bladder cancer	0.00266	0.0268	CbGeAlD
Minocycline—IL1B—prostate gland—urinary bladder cancer	0.00262	0.0264	CbGeAlD
Minocycline—CYCS—renal system—urinary bladder cancer	0.00261	0.0262	CbGeAlD
Minocycline—VEGFA—prostate gland—urinary bladder cancer	0.00258	0.0259	CbGeAlD
Minocycline—CASP3—epithelium—urinary bladder cancer	0.00241	0.0242	CbGeAlD
Minocycline—CASP3—smooth muscle tissue—urinary bladder cancer	0.00232	0.0234	CbGeAlD
Minocycline—CASP3—renal system—urinary bladder cancer	0.00223	0.0225	CbGeAlD
Minocycline—CASP3—urethra—urinary bladder cancer	0.00219	0.0221	CbGeAlD
Minocycline—MMP9—prostate gland—urinary bladder cancer	0.00218	0.022	CbGeAlD
Minocycline—CASP1—female reproductive system—urinary bladder cancer	0.00217	0.0218	CbGeAlD
Minocycline—CYCS—female reproductive system—urinary bladder cancer	0.00209	0.021	CbGeAlD
Minocycline—CASP1—vagina—urinary bladder cancer	0.00196	0.0198	CbGeAlD
Minocycline—IL1B—epithelium—urinary bladder cancer	0.00192	0.0194	CbGeAlD
Minocycline—IL1B—smooth muscle tissue—urinary bladder cancer	0.00185	0.0187	CbGeAlD
Minocycline—VEGFA—smooth muscle tissue—urinary bladder cancer	0.00182	0.0184	CbGeAlD
Minocycline—CASP3—female reproductive system—urinary bladder cancer	0.00179	0.018	CbGeAlD
Minocycline—IL1B—renal system—urinary bladder cancer	0.00178	0.018	CbGeAlD
Minocycline—ALOX5—prostate gland—urinary bladder cancer	0.00173	0.0174	CbGeAlD
Minocycline—VEGFA—urethra—urinary bladder cancer	0.00172	0.0174	CbGeAlD
Minocycline—CASP3—vagina—urinary bladder cancer	0.00162	0.0163	CbGeAlD
Minocycline—MMP9—epithelium—urinary bladder cancer	0.0016	0.0161	CbGeAlD
Minocycline—MMP9—smooth muscle tissue—urinary bladder cancer	0.00154	0.0155	CbGeAlD
Minocycline—MMP9—renal system—urinary bladder cancer	0.00149	0.015	CbGeAlD
Minocycline—IL1B—female reproductive system—urinary bladder cancer	0.00143	0.0144	CbGeAlD
Minocycline—SLC22A11—renal system—urinary bladder cancer	0.00141	0.0142	CbGeAlD
Minocycline—SLC22A7—renal system—urinary bladder cancer	0.00138	0.0138	CbGeAlD
Minocycline—IL1B—vagina—urinary bladder cancer	0.00129	0.013	CbGeAlD
Minocycline—VEGFA—vagina—urinary bladder cancer	0.00127	0.0128	CbGeAlD
Minocycline—CASP1—lymph node—urinary bladder cancer	0.00127	0.0128	CbGeAlD
Minocycline—CYCS—lymph node—urinary bladder cancer	0.00122	0.0123	CbGeAlD
Minocycline—ALOX5—smooth muscle tissue—urinary bladder cancer	0.00122	0.0123	CbGeAlD
Minocycline—MMP9—female reproductive system—urinary bladder cancer	0.00119	0.012	CbGeAlD
Minocycline—SLC22A8—prostate gland—urinary bladder cancer	0.00117	0.0117	CbGeAlD
Minocycline—ALOX5—urethra—urinary bladder cancer	0.00116	0.0116	CbGeAlD
Minocycline—SLC22A11—female reproductive system—urinary bladder cancer	0.00113	0.0114	CbGeAlD
Minocycline—CASP3—lymph node—urinary bladder cancer	0.00105	0.0105	CbGeAlD
Minocycline—ALOX5—female reproductive system—urinary bladder cancer	0.000942	0.00948	CbGeAlD
Minocycline—IL1B—lymph node—urinary bladder cancer	0.000836	0.00841	CbGeAlD
Minocycline—VEGFA—lymph node—urinary bladder cancer	0.000822	0.00828	CbGeAlD
Minocycline—SLC22A8—renal system—urinary bladder cancer	0.000795	0.008	CbGeAlD
Minocycline—MMP9—lymph node—urinary bladder cancer	0.000697	0.00701	CbGeAlD
Minocycline—ALOX5—lymph node—urinary bladder cancer	0.000551	0.00554	CbGeAlD
Minocycline—IL1B—MAPK Signaling Pathway—TP53—urinary bladder cancer	4.49e-05	0.00025	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	4.48e-05	0.000249	CbGpPWpGaD
Minocycline—MMP9—Signaling by SCF-KIT—KRAS—urinary bladder cancer	4.46e-05	0.000248	CbGpPWpGaD
Minocycline—IL1B—Immune System—RBX1—urinary bladder cancer	4.46e-05	0.000248	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	4.45e-05	0.000248	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	4.43e-05	0.000247	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—SRC—urinary bladder cancer	4.4e-05	0.000245	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—IFNA2—urinary bladder cancer	4.34e-05	0.000241	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—NCOR1—urinary bladder cancer	4.33e-05	0.000241	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—TP53—urinary bladder cancer	4.28e-05	0.000238	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—CREBBP—urinary bladder cancer	4.27e-05	0.000238	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—RB1—urinary bladder cancer	4.26e-05	0.000237	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.25e-05	0.000237	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—TYMP—urinary bladder cancer	4.24e-05	0.000236	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—CCND1—urinary bladder cancer	4.11e-05	0.000229	CbGpPWpGaD
Minocycline—VEGFA—VEGFA-VEGFR2 Pathway—HRAS—urinary bladder cancer	4.1e-05	0.000228	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.09e-05	0.000228	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.07e-05	0.000227	CbGpPWpGaD
Minocycline—CYCS—Metabolism—NQO1—urinary bladder cancer	4.01e-05	0.000223	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—PTEN—urinary bladder cancer	3.97e-05	0.000221	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	3.96e-05	0.000221	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.96e-05	0.00022	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.95e-05	0.00022	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—CDKN1A—urinary bladder cancer	3.93e-05	0.000219	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—PTEN—urinary bladder cancer	3.92e-05	0.000218	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	3.88e-05	0.000216	CbGpPWpGaD
Minocycline—VEGFA—Signaling by VEGF—HRAS—urinary bladder cancer	3.87e-05	0.000215	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—EGFR—urinary bladder cancer	3.86e-05	0.000215	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—HDAC4—urinary bladder cancer	3.85e-05	0.000214	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—NAT2—urinary bladder cancer	3.84e-05	0.000213	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.82e-05	0.000213	CbGpPWpGaD
Minocycline—MMP9—Signaling by SCF-KIT—HRAS—urinary bladder cancer	3.79e-05	0.000211	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—RHOA—urinary bladder cancer	3.78e-05	0.00021	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.77e-05	0.00021	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—NCOR1—urinary bladder cancer	3.76e-05	0.000209	CbGpPWpGaD
Minocycline—CASP1—Immune System—FGFR3—urinary bladder cancer	3.76e-05	0.000209	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—CDKN2A—urinary bladder cancer	3.74e-05	0.000208	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—EP300—urinary bladder cancer	3.74e-05	0.000208	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	3.74e-05	0.000208	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—SRC—urinary bladder cancer	3.68e-05	0.000205	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.66e-05	0.000204	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	3.66e-05	0.000204	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—KRAS—urinary bladder cancer	3.65e-05	0.000203	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—SRC—urinary bladder cancer	3.64e-05	0.000202	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	3.6e-05	0.0002	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—ERBB2—urinary bladder cancer	3.5e-05	0.000195	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—CDK4—urinary bladder cancer	3.41e-05	0.00019	CbGpPWpGaD
Minocycline—IL1B—Immune System—IFNA2—urinary bladder cancer	3.41e-05	0.00019	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—CXCL8—urinary bladder cancer	3.39e-05	0.000189	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—KRAS—urinary bladder cancer	3.36e-05	0.000187	CbGpPWpGaD
Minocycline—CYCS—Metabolism—GSTP1—urinary bladder cancer	3.35e-05	0.000186	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—HDAC4—urinary bladder cancer	3.34e-05	0.000186	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—RRM2—urinary bladder cancer	3.31e-05	0.000184	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.28e-05	0.000183	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—RHOA—urinary bladder cancer	3.28e-05	0.000183	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	3.26e-05	0.000181	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	3.25e-05	0.000181	CbGpPWpGaD
Minocycline—IL1B—Immune System—S100B—urinary bladder cancer	3.23e-05	0.00018	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—EGFR—urinary bladder cancer	3.23e-05	0.00018	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—GLI1—urinary bladder cancer	3.22e-05	0.000179	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.21e-05	0.000179	CbGpPWpGaD
Minocycline—CASP1—Immune System—CREBBP—urinary bladder cancer	3.2e-05	0.000178	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—EGFR—urinary bladder cancer	3.19e-05	0.000177	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.19e-05	0.000177	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—RBX1—urinary bladder cancer	3.18e-05	0.000177	CbGpPWpGaD
Minocycline—CASP1—Immune System—CDH1—urinary bladder cancer	3.17e-05	0.000177	CbGpPWpGaD
Minocycline—CYCS—Metabolism—TYMS—urinary bladder cancer	3.11e-05	0.000173	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—PPARG—urinary bladder cancer	3.1e-05	0.000173	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—HRAS—urinary bladder cancer	3.1e-05	0.000172	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—PLAU—urinary bladder cancer	3.08e-05	0.000171	CbGpPWpGaD
Minocycline—CYCS—Metabolism—NCOR1—urinary bladder cancer	3.07e-05	0.000171	CbGpPWpGaD
Minocycline—CYCS—Metabolism—GSTM1—urinary bladder cancer	3.07e-05	0.000171	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—HPGDS—urinary bladder cancer	3.07e-05	0.000171	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—ENO2—urinary bladder cancer	3.07e-05	0.000171	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.06e-05	0.00017	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—CDKN1A—urinary bladder cancer	3.06e-05	0.00017	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.05e-05	0.00017	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—ERBB2—urinary bladder cancer	3.04e-05	0.000169	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.03e-05	0.000169	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—KRAS—urinary bladder cancer	3.01e-05	0.000168	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—TSC1—urinary bladder cancer	2.99e-05	0.000167	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—CREBBP—urinary bladder cancer	2.98e-05	0.000166	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—GSTT1—urinary bladder cancer	2.97e-05	0.000166	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—CDK4—urinary bladder cancer	2.96e-05	0.000165	CbGpPWpGaD
Minocycline—CYCS—Metabolism—GPX1—urinary bladder cancer	2.94e-05	0.000164	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.93e-05	0.000163	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—EP300—urinary bladder cancer	2.91e-05	0.000162	CbGpPWpGaD
Minocycline—CYCS—Metabolism—ERCC2—urinary bladder cancer	2.89e-05	0.000161	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—HRAS—urinary bladder cancer	2.85e-05	0.000159	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—JAG1—urinary bladder cancer	2.85e-05	0.000159	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—GLI1—urinary bladder cancer	2.8e-05	0.000156	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—SRC—urinary bladder cancer	2.77e-05	0.000154	CbGpPWpGaD
Minocycline—CYCS—Metabolism—MTHFR—urinary bladder cancer	2.72e-05	0.000151	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.7e-05	0.00015	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—RHOA—urinary bladder cancer	2.7e-05	0.00015	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—PPARG—urinary bladder cancer	2.69e-05	0.00015	CbGpPWpGaD
Minocycline—CASP1—Immune System—ERBB2—urinary bladder cancer	2.68e-05	0.000149	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—MMP9—urinary bladder cancer	2.6e-05	0.000145	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—HRAS—urinary bladder cancer	2.59e-05	0.000144	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—CREBBP—urinary bladder cancer	2.59e-05	0.000144	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—HRAS—urinary bladder cancer	2.56e-05	0.000142	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—CREBBP—urinary bladder cancer	2.54e-05	0.000141	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—IGF1—urinary bladder cancer	2.51e-05	0.000139	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—ERBB2—urinary bladder cancer	2.5e-05	0.000139	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—NQO1—urinary bladder cancer	2.47e-05	0.000138	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL2—urinary bladder cancer	2.43e-05	0.000135	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—EGFR—urinary bladder cancer	2.42e-05	0.000135	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—SRC—urinary bladder cancer	2.4e-05	0.000134	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.4e-05	0.000133	CbGpPWpGaD
Minocycline—IL1B—Immune System—FGFR3—urinary bladder cancer	2.35e-05	0.000131	CbGpPWpGaD
Minocycline—SLC22A11—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.34e-05	0.00013	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—RHOA—urinary bladder cancer	2.34e-05	0.00013	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—S100B—urinary bladder cancer	2.31e-05	0.000128	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—RHOA—urinary bladder cancer	2.3e-05	0.000128	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—KRAS—urinary bladder cancer	2.29e-05	0.000127	CbGpPWpGaD
Minocycline—CASP1—Immune System—CDKN1A—urinary bladder cancer	2.29e-05	0.000127	CbGpPWpGaD
Minocycline—CASP1—Immune System—PTEN—urinary bladder cancer	2.28e-05	0.000127	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—RBX1—urinary bladder cancer	2.21e-05	0.000123	CbGpPWpGaD
Minocycline—CYCS—Metabolism—PPARG—urinary bladder cancer	2.2e-05	0.000123	CbGpPWpGaD
Minocycline—CASP1—Immune System—EP300—urinary bladder cancer	2.18e-05	0.000121	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—ERBB2—urinary bladder cancer	2.17e-05	0.000121	CbGpPWpGaD
Minocycline—SLC22A7—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.13e-05	0.000118	CbGpPWpGaD
Minocycline—CASP1—Immune System—SRC—urinary bladder cancer	2.12e-05	0.000118	CbGpPWpGaD
Minocycline—CYCS—Metabolism—CREBBP—urinary bladder cancer	2.12e-05	0.000118	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—EGFR—urinary bladder cancer	2.1e-05	0.000117	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.09e-05	0.000116	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—TP53—urinary bladder cancer	2.08e-05	0.000116	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TSC1—urinary bladder cancer	2.08e-05	0.000116	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—NCOR1—urinary bladder cancer	2.07e-05	0.000115	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—GSTP1—urinary bladder cancer	2.06e-05	0.000115	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—EP300—urinary bladder cancer	2.03e-05	0.000113	CbGpPWpGaD
Minocycline—IL1B—Immune System—CREBBP—urinary bladder cancer	2e-05	0.000111	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.99e-05	0.000111	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—KRAS—urinary bladder cancer	1.99e-05	0.000111	CbGpPWpGaD
Minocycline—IL1B—Immune System—CDH1—urinary bladder cancer	1.98e-05	0.00011	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—JAG1—urinary bladder cancer	1.98e-05	0.00011	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—SRC—urinary bladder cancer	1.97e-05	0.00011	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—HRAS—urinary bladder cancer	1.95e-05	0.000108	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—IL2—urinary bladder cancer	1.93e-05	0.000107	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—RBX1—urinary bladder cancer	1.92e-05	0.000107	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—TYMS—urinary bladder cancer	1.92e-05	0.000107	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—NCOR1—urinary bladder cancer	1.89e-05	0.000105	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—GSTM1—urinary bladder cancer	1.89e-05	0.000105	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—MMP9—urinary bladder cancer	1.86e-05	0.000103	CbGpPWpGaD
Minocycline—CASP1—Immune System—EGFR—urinary bladder cancer	1.86e-05	0.000103	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—TERT—urinary bladder cancer	1.83e-05	0.000102	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—GPX1—urinary bladder cancer	1.81e-05	0.000101	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TSC1—urinary bladder cancer	1.8e-05	0.0001	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.79e-05	9.95e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—ERCC2—urinary bladder cancer	1.78e-05	9.91e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—EP300—urinary bladder cancer	1.76e-05	9.81e-05	CbGpPWpGaD
Minocycline—CASP1—Immune System—KRAS—urinary bladder cancer	1.75e-05	9.76e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—PTGS2—urinary bladder cancer	1.73e-05	9.64e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—EGFR—urinary bladder cancer	1.73e-05	9.63e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—EP300—urinary bladder cancer	1.73e-05	9.62e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—JAG1—urinary bladder cancer	1.72e-05	9.55e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—SRC—urinary bladder cancer	1.71e-05	9.54e-05	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—HRAS—urinary bladder cancer	1.69e-05	9.41e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—SRC—urinary bladder cancer	1.68e-05	9.36e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—FGFR3—urinary bladder cancer	1.68e-05	9.34e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—ERBB2—urinary bladder cancer	1.67e-05	9.32e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—MTHFR—urinary bladder cancer	1.67e-05	9.32e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—TNF—urinary bladder cancer	1.65e-05	9.17e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—KRAS—urinary bladder cancer	1.63e-05	9.1e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—ESR1—urinary bladder cancer	1.63e-05	9.07e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—S100B—urinary bladder cancer	1.6e-05	8.91e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL2—urinary bladder cancer	1.52e-05	8.44e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—PTEN—urinary bladder cancer	1.51e-05	8.41e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—EGFR—urinary bladder cancer	1.5e-05	8.36e-05	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.49e-05	8.3e-05	CbGpPWpGaD
Minocycline—CASP1—Immune System—HRAS—urinary bladder cancer	1.49e-05	8.3e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—EP300—urinary bladder cancer	1.44e-05	8.02e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—NCOR1—urinary bladder cancer	1.44e-05	8.01e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—CDKN1A—urinary bladder cancer	1.43e-05	7.96e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—TNF—urinary bladder cancer	1.43e-05	7.96e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CREBBP—urinary bladder cancer	1.43e-05	7.95e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—PTEN—urinary bladder cancer	1.43e-05	7.94e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—KRAS—urinary bladder cancer	1.42e-05	7.9e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IGF1—urinary bladder cancer	1.41e-05	7.85e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—KRAS—urinary bladder cancer	1.39e-05	7.75e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—S100B—urinary bladder cancer	1.39e-05	7.74e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—HRAS—urinary bladder cancer	1.39e-05	7.73e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—EP300—urinary bladder cancer	1.36e-05	7.58e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PPARG—urinary bladder cancer	1.36e-05	7.55e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—SRC—urinary bladder cancer	1.32e-05	7.37e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CREBBP—urinary bladder cancer	1.3e-05	7.26e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—RHOA—urinary bladder cancer	1.29e-05	7.19e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TERT—urinary bladder cancer	1.27e-05	7.06e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—NCOR1—urinary bladder cancer	1.25e-05	6.96e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—TP53—urinary bladder cancer	1.24e-05	6.88e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—HRAS—urinary bladder cancer	1.21e-05	6.71e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—ERBB2—urinary bladder cancer	1.2e-05	6.66e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—HRAS—urinary bladder cancer	1.18e-05	6.58e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—FGFR3—urinary bladder cancer	1.16e-05	6.48e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—EGFR—urinary bladder cancer	1.16e-05	6.46e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CXCL8—urinary bladder cancer	1.13e-05	6.31e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—ESR1—urinary bladder cancer	1.13e-05	6.29e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TERT—urinary bladder cancer	1.1e-05	6.13e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—KRAS—urinary bladder cancer	1.1e-05	6.1e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IL2—urinary bladder cancer	1.08e-05	6.03e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PTGS2—urinary bladder cancer	1.07e-05	5.94e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCND1—urinary bladder cancer	1.06e-05	5.88e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—MMP9—urinary bladder cancer	1.03e-05	5.71e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CDKN1A—urinary bladder cancer	1.02e-05	5.69e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—PTEN—urinary bladder cancer	1.02e-05	5.68e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—FGFR3—urinary bladder cancer	1.01e-05	5.63e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CREBBP—urinary bladder cancer	9.91e-06	5.52e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—ESR1—urinary bladder cancer	9.82e-06	5.46e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IGF1—urinary bladder cancer	9.79e-06	5.45e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—EP300—urinary bladder cancer	9.72e-06	5.41e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—SRC—urinary bladder cancer	9.46e-06	5.26e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—HRAS—urinary bladder cancer	9.32e-06	5.19e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PTEN—urinary bladder cancer	9.31e-06	5.18e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—RHOA—urinary bladder cancer	8.97e-06	4.99e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—EP300—urinary bladder cancer	8.88e-06	4.94e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CREBBP—urinary bladder cancer	8.6e-06	4.79e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IGF1—urinary bladder cancer	8.5e-06	4.73e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—MYC—urinary bladder cancer	8.47e-06	4.72e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—ERBB2—urinary bladder cancer	8.3e-06	4.62e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—EGFR—urinary bladder cancer	8.29e-06	4.61e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CXCL8—urinary bladder cancer	7.87e-06	4.38e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—KRAS—urinary bladder cancer	7.83e-06	4.36e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—RHOA—urinary bladder cancer	7.78e-06	4.33e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IL2—urinary bladder cancer	7.52e-06	4.19e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CCND1—urinary bladder cancer	7.33e-06	4.08e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—ERBB2—urinary bladder cancer	7.21e-06	4.01e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CDKN1A—urinary bladder cancer	7.09e-06	3.95e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PTEN—urinary bladder cancer	7.08e-06	3.94e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—TP53—urinary bladder cancer	6.96e-06	3.87e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CXCL8—urinary bladder cancer	6.83e-06	3.8e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—EP300—urinary bladder cancer	6.75e-06	3.76e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—HRAS—urinary bladder cancer	6.66e-06	3.7e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—SRC—urinary bladder cancer	6.56e-06	3.65e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IL2—urinary bladder cancer	6.53e-06	3.63e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCND1—urinary bladder cancer	6.37e-06	3.54e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—MMP9—urinary bladder cancer	6.18e-06	3.44e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CDKN1A—urinary bladder cancer	6.16e-06	3.43e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PTEN—urinary bladder cancer	6.15e-06	3.42e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—MYC—urinary bladder cancer	5.88e-06	3.27e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—EP300—urinary bladder cancer	5.86e-06	3.26e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—EGFR—urinary bladder cancer	5.75e-06	3.2e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—SRC—urinary bladder cancer	5.7e-06	3.17e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—KRAS—urinary bladder cancer	5.44e-06	3.03e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—MYC—urinary bladder cancer	5.11e-06	2.84e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—EGFR—urinary bladder cancer	4.99e-06	2.78e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TP53—urinary bladder cancer	4.83e-06	2.69e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—KRAS—urinary bladder cancer	4.72e-06	2.63e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—HRAS—urinary bladder cancer	4.62e-06	2.57e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TP53—urinary bladder cancer	4.19e-06	2.33e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—HRAS—urinary bladder cancer	4.01e-06	2.23e-05	CbGpPWpGaD
